Oligomycin B
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Oligomycin B is a mitochondrial F1FO ATP synthase inhibitor.
The mitochondrial F1F0 ATP synthase is responsible for the ATP production in mammals via a rotary catalytic mechanism. Studies also show that the F1F0 ATP synthase can switch to an ATP hydrolase, which occurs under conditions during myocardial ischemia.
In vitro: Previous study found that oligomycin B and aurovertin B were able to inhibit both the synthase and the hydrolase function, which not only rendered them difficult to be experimentally used, but also precluded them from being therapeutics. Aurovertin B bound between the subunits catalytic F1 domain of the F1F0 ATPase, where it prevented the conformational changes required for the catalytic cycle of this enzyme, whereas oligomycin bound to the F0 domain and blocked proton flow [1].
In vivo: In a previous animal study, intracranial pressure measurements were performed in SD rats treated by intraperitoneal injection of vehicle, cyclosporine A, or oligomycin B. It was found that cerebral edema and mitochondrial impairment could be significantly worsened by treatment with oligomycin B, whereas a noticeable improvement could be observed in animals that received injections of cyclosporine A [2].
Clinical trial: Up to now, oligomycin B is still in the preclinical development stage.
References:
[1] G. J. Grover and J. Malm. Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia. Cardiovasc.Ther. 26, 287-296 (2008).
[2] Vlodavsky E, Palzur E, Shehadeh M, Soustiel JF. Post-traumatic cytotoxic edema is directly related to mitochondrial function. J Cereb Blood Flow Metab. 2017 Jan;37(1):166-177.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 805.1 |
Cas No. | 11050-94-5 |
Formula | C45H72O12 |
Solubility | ≤30mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide |
Chemical Name | (1S,2'R,4E,5'R,6R,6'R,7S,8R,10S,11S,12R,14S,15R,16S,18E,20E,22S,25R,28R,29S)-22-ethyl-5',6'-dihydro-7,11,14,15-tetrahydroxy-6'-[(2S)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethyl-spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-[2H]pyra |
SDF | Download SDF |
Canonical SMILES | O=C([C@H](C)[C@@H](O)[C@H](C)/C=C/1)[C@@H](C)[C@H](O)[C@@H](C)C([C@](O)(C)[C@H](O)[C@@H](C)C/C=C/C=C/[C@](CC)([H])CC[C@]2([H])[C@H](C)[C@]([C@@H](C)[C@]3(C(C[C@@H](C)[C@](C[C@@H](O)C)([H])O3)=O)O2)([H])OC1=O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |